Key Points:
- With the recommendation to start colorectal cancer (CRC) screening at age 45, there is a significant increase in the number of individuals eligible for screening, creating a demand for more screening options.
- Dr. Aasma Shaukat from NYU Grossman School of Medicine discussed the potential of blood-based tests as game changers for population screening, especially for the younger age group.
- Studies suggest higher adherence to blood-based tests compared to current modalities, including stool-based tests like the fecal immunochemical test (FIT).
- These screenings involve circulating tumor DNA or cell-free DNA technologies, enhanced by artificial intelligence and machine learning. Galleri (Grail) and Guardant Shield (Guardant) are examples of lab-developed tests currently available.
- Large population-based studies are being conducted by Guardant and Freenome for their tests, aiming for FDA approval.